Foresee Pharmaceuticals Receives the Fourth Positive Recommendation from the DSMB to Continue the Casppian Ph3 Study, for Central Precocious Puberty (CPP)

The independent Data and Safety Monitoring Board (DSMB) recommended the continuation of the study as planned. The Casppian study design included periodic evaluations and long-term safety monitoring for up to a total of 12 months following the first injection. There has been no safety...